GC
RIGL icon

Guggenheim Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Guggenheim Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,000
Closed -$32K – 3020
2015
Q2 		$32K Sell
1,000
-174
-15% -$6.65K ﹤0.01% 2978
2015
Q1 		$42K Buy
1,174
+70
+6% +$1.92K ﹤0.01% 2943
2014
Q4 		$25K Buy
+1,104
New +$22.3K ﹤0.01% 2959
2014
Q2 		– Sell
-1,061
Closed -$41K – 3288
2014
Q1 		$41K Sell
1,061
-92
-8% -$3.28K ﹤0.01% 3161
2013
Q4 		$33K Buy
+1,153
New +$33.8K ﹤0.01% 3090

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Guggenheim Capital's RIGL Position: Q3 2015 in Review

Guggenheim Capital sold out of Rigel Pharmaceuticals (RIGL) in Q3 2015, closing a stake of 1,000 shares — an estimated $32K sold.

Guggenheim Capital first reported a position in RIGL in Q4 2013 and held it in 5 quarters. The position peaked at $42K in Q1 2015. 122 funds tracked by Wall St. Rank hold RIGL as of Q3 2015.

  • Guggenheim Capital reported no remaining Rigel Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Guggenheim Capital sold 1,000 Rigel Pharmaceuticals shares in Q3 2015, an estimated $32K.
  • Guggenheim Capital first reported a position in Rigel Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Guggenheim Capital's Rigel Pharmaceuticals position peaked at $42K in Q1 2015.
  • 122 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2015.

Based on Guggenheim Capital's 13F filing for Q3 2015, filed 16 Nov 2015.